SCHEMBL4728744

SCHEMBL4728744

CC(C)C(=O)Nc1ccc2c(c1)c1ccccc1n2C

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.74
LMNA P02545 3/20 0.74
NPY5R Q15761 6/20 0.65
GAA P10253 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MEN1 O00255 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KDM4E B2RXH2 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
RORC P51449 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974078 0.85 MAPT (1.00) MAPTLMNANPY5RGAAALDH1A1
SCHEMBL4725134 0.83 MAPT (0.77) MAPTLMNANPY5RGAAALDH1A1
SCHEMBL17117440 0.81 NPY5R (0.67) MAPTLMNANPY5RALDH1A1KMT2A
SCHEMBL17117305 0.81 NPY5R (0.67) MAPTLMNANPY5RALDH1A1KMT2A
SCHEMBL4727925 0.80 NPY5R (0.65) MAPTLMNANPY5RALDH1A1HPGD
SCHEMBL4728699 0.80 NPY5R (0.78) MAPTLMNANPY5RKMT2ASMN1; SMN2
SCHEMBL3727171 0.79 NPY5R (0.64) MAPTLMNANPY5RALDH1A1HPGD
SCHEMBL31005266 0.79 NPY5R (1.00) MAPTLMNANPY5RGAAKMT2A
SCHEMBL1593413 0.79 NPY5R (1.00) MAPTLMNANPY5RGAAKMT2A
SCHEMBL6763360 0.78 NPY5R (0.62) MAPTLMNANPY5RGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147752-A1 Carbazole derivatives for the treatment of NPY related diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-07-29 US claimed
WO-2008021745-A2 HEPATITIS C VIRUS ENTRY INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed
US-20040147752-A1 Carbazole derivatives for the treatment of NPY related diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147752-A1 Carbazole derivatives for the treatment of NPY related diseases NPY4R, NPY5R, NPY1R MAPT 1696/4885LMNA 3205/4885NPY5R 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.